Vedolizumab Market

Vedolizumab API market is projected to grow at a CAGR of 6% between 2025 and 2035, the market growth is driven by the rising global prevalence of inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn’s disease. As vedolizumab is a gut-selective integrin antagonist with proven efficacy and a favorable safety profile, its demand continues to expand, not only in originator drugs but also in the growing biosimilar development space.

The key segment dominating the market is Ulcerative Colitis, accounting for the highest share of API demand. This is due to the higher diagnosis rates, the chronic nature of the disease, and the increasing adoption of biologic therapies as frontline treatment. Pharmaceutical companies are focusing on expanding their Vedolizumab-based product lines into both first-line and second-line therapies, further boosting API consumption.

Geographically, North America, particularly the US, leads the global vedolizumab API market, supported by strong biologics research, high healthcare expenditure, and the early adoption of biosimilars. Europe, especially countries like Germany and the UK, is another significant market, with favorable regulatory support for biosimilar launches. Meanwhile, India and South Korea are emerging as key hubs for cost-effective API manufacturing and contract development services, fueling the Asia-Pacific growth.

Prominent players in the market include Takeda Pharmaceuticals (originator of Entyvio), Samsung Biologics, Lonza Group, and several specialized Contract Development and Manufacturing Organizations (CDMOs) such as WuXi Biologics and Samsung Bioepis (for biosimilars). New entrants are also focusing on creating high-purity research-grade Vedolizumab APIs to cater to the early-stage R&D market, intensifying competition.